Atlas Trials

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Clinical trial NCT04057898 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04057898
Sponsor
MediciNova
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Amyotrophic Lateral Sclerosis
Start date
2020-05-28
Primary completion
2027-04-01
Enrollment
234

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.